BioHedge Weekly: Biotech Hedge Fund 13D and 13G Filing Tracker
13D/13G filings from biotech-focused institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
RA Capital Management initiated new 5.8% position in Editas Medicine, Inc.. 1 filing this week, all passive.
BVF Partners L.P. initiated new 5.3% position in a biotech
RA Capital Management initiated new 6.3% position in Sana Biotechnology, Inc.
Cormorant Asset Management, LP initiated new 7.6% position in Rallybio Corp
EcoR1 Capital increased ATARA BIOTHERAPEUTICS INC stake to 17.4% (up 7.5pp)
RA Capital Management initiated new 9.9% position in Prelude Therapeutics Inc
Perceptive Advisors initiated new 5.4% position in SUTRO BIOPHARMA, INC.
Perceptive Advisors initiated new 10.0% position in KIORA PHARMACEUTICALS INC
RA Capital Management initiated new 9.9% position in OnKure, Inc.
RA Capital Management initiated new 9.9% position in Karyopharm Therapeutics Inc.
Baker Brothers Advisors increased Celcuity Inc. stake to 20.0% (up 1.1pp)
Perceptive Advisors initiated new 5.3% position in Relay Therapeutics, Inc.
Perceptive Advisors reduced Solid Biosciences Inc. stake to 12.9% (down 2.7pp)
Deerfield Management reduced Larimar Therapeutics, Inc. stake to 34.4% (down 1.4pp)
BIOS Partners reduced Lantern Pharma Inc. stake to 8.6% (down 1.4pp)
BVF Partners L.P. initiated new 10.0% position in IMMUNIC INC
RA Capital Management initiated new 9.9% position in ALX Oncology Inc.
RA Capital Management initiated new 7.0% position in HELIX ACQUISITION CORP II
Perceptive Advisors initiated new 7.3% position in SAB BIOTHERAPEUTICS INC